Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

• Published in: Gut Vol. 29; no. 5; pp. 675 - 681
• Main Authors: Galmiche, J P, Brandstätter, G, Evreux, M, Hentschel, E, Kerstan, E, Kratochvil, P, Reichel, W, Schütze, K, Soule, J C, Vitaux, J
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01-05-1988; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Aged; Biological and medical sciences; Cimetidine - therapeutic use; Cisapride; Clinical Trials as Topic; Digestive system; Double-Blind Method; Drug Combinations; Esophagitis, Peptic - drug therapy; Esophagoscopy; Female; Heartburn - drug therapy; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Piperidines - therapeutic use; Random Allocation; Therapeutic efficiency; Human; Gastroesophageal reflux; Drug combination; Chemotherapy; Treatment; Multicenter study; Double blind study; Digestive diseases; Controlled therapeutic trial; Antihistaminic
• ISSN: 0017-5749; 1468-3288; 1458-3288
• DOI: 10.1136/gut.29.5.675

Combined treatment with cimetidine 1 g daily and cisapride 40 mg daily in patients with endoscopically diagnosed severe reflux oesophagitis was compared with single drug therapy (cimetidine and placebo). At the end of the six to 12 weeks treatment, 11 (46%) of the 24 patients under single drug therapy were endoscopically healed and three were improved. In contrast, 16 (70%) of the 23 patients under combined therapy were healed and all of the remainder were improved (p = 0.025). The severity of diurnal and nocturnal heartburn, decreased significantly more (p less than 0.05) on cimetidine + cisapride than on cimetidine + placebo. The combined treatment was well tolerated. These results suggest that combined therapy with cisapride and cimetidine may be useful in patients with severe reflux oesophagitis.